Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A Edesa Biotech, Inc. Filed by: Stonepine Capital Management, LLC

May 15, 2026 5:19 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 8,891,951 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 8,891,951 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 8,891,951 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 8,891,951 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.


SCHEDULE 13G



Stonepine Capital Management, LLC
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:05/15/2025
Stonepine Capital, L.P.
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
Date:05/15/2025
Stonepine GP, LLC
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:05/15/2025
Jon M. Plexico
Signature:/s/ Jon M. Plexico
Name/Title:Reporting person
Date:05/15/2025
Exhibit Information

Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

ATTACHMENTS / EXHIBITS

exhibit99.htm

Categories

SEC Filings